S&P 500
7,398.80
-0.03%
Dow Jones
51,778.50
-0.15%
Nasdaq 100
29,512.60
-0.06%
Russell 2000
2,980.68
-0.05%
FTSE 100
10,453.50
-0.08%
Nikkei 225
69,424.70
+0.15%

Health and Healthcare

J&J, Pfizer Halt Development of Alzheimer’s Drug

Photo of 247sam
By 247sam Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Invalid Image
Johnson & Johnson Inc. (NYSE: JNJ) and Pfizer Inc. (NYSE: PFE) both announced they are stopping development of a drug to treat patients with mild to moderate Alzheimer’s after the drug failed a second clinical trial.

The companies both noted the drug, bapineuzumab, did not improve the condition of Alzheimer’s patients compared to a placebo.

Johnson & Johnson will take a $300 million to $400 million charge in the third quarter.

Shares of Pfizer are down 2.51% in after-hours trading. Shares of Johnson & Johnson are up 0.21%.

Samuel Weigley

DISCLOSURE:
INVESTMENTS ARE NOT FDIC INSURED • ARE NOT BANK GUARANTEED • MAY LOSE VALUE Brokerage and Active investing products offered through SoFi Securities LLC, member FINRA(www.finra.org)/SIPC(www.sipc.org). Advisory services are offered by SoFi Wealth LLC, an SEC-registered investment adviser. Information about SoFi Wealth’s advisory operations, services, and fees is set forth in SoFi Wealth’s current Form ADV Part 2 (Brochure), a copy of which is available upon request and at www.adviserinfo.sec.gov. Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 30 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Other fees, such as exchange fees, may apply. Please view our fee disclosure to view a full listing of fees. Investing in alternative investments and/or strategies may not be suitable for all investors and involves unique risks, including the risk of loss. An investor should consider their individual circumstances and any investment information, such as a prospectus, prior to investing. Interval Funds are illiquid instruments, the ability to trade on your timeline may be restricted. Brokerage and Active investing products offered through SoFi Securities LLC, Member FINRA(www.finra.org) /SIPC(www.sipc.org). There are limitations with fractional shares to consider before investing. During market hours fractional share orders are transmitted immediately in the order received. There may be system delays from receipt of your order until execution and market conditions may adversely impact execution prices. Outside of market hours orders are received on a not held basis and will be aggregated for each security then executed in the morning trade window of the next business day at market open. Share will be delivered at an average price received for executing the securities through a single batched order. Fractional shares may not be transferred to another firm. Fractional shares will be sold when a transfer or closure request is initiated. Please consider that selling securities is a taxable event. Options involve risks, including substantial risk of loss and the possibility an investor may lose the entire investment Before trading options please review the Characteristics and Risks of Standardized Options  Investing in an Initial Public Offering (IPO) involves substantial risk, including the risk of loss. Further, there are a variety of risk factors to consider when investing in an IPO, including but not limited to, unproven management, significant debt, and lack of operating history. For a comprehensive discussion of these risks please refer to SoFi Securities’ IPO Risk Disclosure Statement This should not be considered a recommendation to participate in IPOs and investors should carefully read the offering prospectus to determine whether an offering is consistent with their investment objectives, risk tolerance, and financial situation. New offerings generally have high demand and there are a limited number of shares available for distribution to participants. Many customers may not be allocated shares and share allocations may be significantly smaller than the shares requested in the customer’s initial offer (Indication of Interest). For more information on the allocation process please visit IPO Allocation.
Follow 24/7 Wall St. on Google
Photo of 247sam
About the Author 247sam →

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Hospital Executives Are Quietly Stacking a Second 401(k) Plan and Saving $40,000 in Taxes
Marc Guberti |

Hospital Executives Are Quietly Stacking a Second 401(k) Plan and Saving $40,000 in Taxes
Widowed Twice, He Can Only Claim on One Record, Worth $2,600 a Month, Not Both
Gerelyn Terzo |

Widowed Twice, He Can Only Claim on One Record, Worth $2,600 a Month, Not Both

Continue Reading

The List of Failed Alzheimer’s Drug Treatments Keeps Growing
Jon C. Ogg |

The List of Failed Alzheimer’s Drug Treatments Keeps Growing

If there is one cure or one treatment that could be the proverbial Holy Grail for a pharmaceutical or biotech…

Paul Ausick |

Pfizer’s Alzheimer’s Drug Fails Trial

A new treatment for Alzheimer’s disease from Pfizer Inc. (NYSE: PFE) and partner Elan Corp. plc (NYSE: ELN) has failed…

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure
Jon C. Ogg |

2 Pharma Giants Shine as Wall Street Brings Strong IPOs for Cortexyme and NextCure

It's an impressive day when two IPOs are well received when drug-selling revenues are unlikely for quite some time, and…

Jon C. Ogg |

BioHealth Daily: Forgetting Alzheimers (PRAN, PFE, NVS, FRX)

It’s the BioHeath Daily for key developments in drugs, biotech, and medical developments.  Prana Biotechnology Ltd. (NASDAQ: PRAN) is often…

Paul Ausick |

Alzheimer’s Drug Shows Some Success (LLY, PFE, ELN)

Drugmaker Eli Lilly & Co. (NYSE: LLY) announced this morning that the company’s solanezumab treatment for Alzheimer’s disease failed to…

The 2016 Bullish and Bearish Case for Pfizer, Merck, Johnson & Johnson
Chris Lange |

The 2016 Bullish and Bearish Case for Pfizer, Merck, Johnson & Johnson

24/7 Wall Street has evaluated three major Dow components in the pharmaceutical industry and presented the bullish and bearish case…

Douglas A. McIntyre |

Barron’s Alzheimer’s Article Only Scratches the Surface

Stock Tickers: WYE, NRMX, ELN, NVS, PFE, LLY, JNJ, AZN, TRGT, SNH, SRZ, BKD, ALC, HCR, ESC, MYGN, FRX, NYMX,…

Jon C. Ogg |

Elan’s Spin-Off Creates Buyout Hopes (ELN, BIIB, ALKS, PFE)

Elan Corporation, plc (NYSE: ELN) may be surging on news that it is going to spin off its drug research unit,…

Douglas A. McIntyre |

Major Biotech Movers (AGEN, CEGE, ENCY, IDMI, IMCL, ONXX, PFE, NTII, OXGN, PSDV, SIRT)

Antigenics Inc.  (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this…

Top Gaining Stocks

Axon Enterprise
AXON • Vol: 1,135,209
CDW
CDW • Vol: 2,437,574
GE HealthCare
GEHC • Vol: 8,107,469
IBM
IBM • Vol: 16,103,112
Charter Communications
CHTR • Vol: 2,972,111

Top Losing Stocks

Micron Technology
MU • Vol: 60,251,824
ON Semiconductor
ON • Vol: 15,490,005
Enphase Energy
ENPH • Vol: 6,293,491
Lam Research
LRCX • Vol: 16,065,247
Microchip Technology
MCHP • Vol: 18,305,346